The Canadian Hemophilia Society (CHS) is proud to put out its call for applications for its new research program created in collaboration with Bayer and ADVANCE Canada.
The Canadian Hemophilia Society – Bayer ADVANCE Canada Research Program was created to engage Canadian hemophilia treaters in activities to identify and research key issues in the ageing hemophilia population.
The research program will support studies that aim to:
• Identify and provide insight into key issues associated with the ageing hemophilia population
• Identify how management of age-related co-morbidities should be adapted to those with hemophilia
• Create and deliver evidence-based information to health care practitioners (HCPs), the public and policy makers that will lead to improved care and QoL for older Canadians living with hemophilia
All completed application forms and support documents must arrive at the National Office of the Canadian Hemophilia Society on or before August 31, 2018. If the CHS receives the application after the deadline date but it is postmarked on or before the deadline date, then it is considered to have been submitted on time. The names of the successful applicants will be announced by October, 2018.
Additional information, the eligibility criteria and conditions for the research program as well as the application form can be found on our website at this link: https://www.hemophilia.ca/research-chs-bayer-advance-canada-research-program/
Please feel free to distribute this information to others who may be interested in applying. For your convenience, a copy of the application form is attached to this email. The research must be conducted in Canada by researchers affiliated with Canadian universities and not-for-profit-related organizations.
If you require further information, please do not hesitate to contact Mr. Michel Long at the CHS National Office at 1-800-668-2686 or by e-mail at email@example.com.